^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma
Published date:
12/01/2021
Excerpt:
The combination of lenvatinib and everolimus is FDA- and EMA-approved after TKI failure [II, B; ESMO-MCBS v1.1 score: 4] and could be considered following progression after first-line TKI monotherapy or a TKI in combination with an immune checkpoint inhibitor [IV, C].
Secondary therapy:
everolimus
DOI:
https://doi.org/10.1016/j.esmoop.2021.100304
Source:
Published date:
02/03/2021
Excerpt:
Subsequent Therapy for Clear Cell Histology...Preferred Regimens...Lenvatinib + everolimus was changed to a category 2A recommendation.
Secondary therapy:
everolimus
